GSK (NYSE:GSK) Stock Acquired Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of GSK plc (NYSE:GSK). In a filing disclosed on November 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in GSK stock on November 25th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of Nestlé (OTCMKTS:NSRGY) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 11/25/2024.
• Purchased $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 11/25/2024.

GSK Stock Performance

NYSE:GSK opened at $34.33 on Friday. The stock’s fifty day moving average is $37.42 and its 200 day moving average is $40.09. GSK plc has a fifty-two week low of $32.83 and a fifty-two week high of $45.92. The firm has a market capitalization of $71.15 billion, a PE ratio of 22.29, a PEG ratio of 1.31 and a beta of 0.66. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.58%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio is 99.35%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on GSK shares. Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus price target of $43.25.

Insider Activity

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.00% of the company’s stock.

Institutional Trading of GSK

Several institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC lifted its position in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares during the period. Primecap Management Co. CA increased its stake in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after buying an additional 342,365 shares during the period. Provident Trust Co. increased its stake in shares of GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after buying an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC increased its stake in shares of GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares during the period. 15.74% of the stock is currently owned by institutional investors.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2025. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2024 election. Marjorie Taylor Greene earned a bachelor’s degree in business administration from the University of Georgia. Greene’s career experience includes co-owning construction company Taylor Commercial and founding and owning a CrossFit gym.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.